Regional citrate anticoagulation for continuous renal replacement therapy: a prospective study in a resource-limited intensive care unit from Vietnam.
越南資源有限的重症監護病房中持續性腎臟替代療法的區域檸檬酸抗凝劑:一項前瞻性研究。
J Nephrol 2025-03-17
Regional Citrate Anticoagulation versus No Anticoagulation for CKRT in Patients with Liver Failure with Increased Bleeding Risk.
肝衰竭患者進行 CKRT 時區域性檸檬酸抗凝血與無抗凝血比較,對於增加出血風險的病人。
Clin J Am Soc Nephrol 2024-02-14
A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy.
Epoprostenol 與肝素和檸檬酸鹽在接受連續腎臟替代治療的兒童中抗凝作用和安全性的比較。
Blood Purif 2024-07-11
CaCl2-citrate regional anticoagulation with CVVHD leads to unwanted chloride loading compared to CVVH with systemic anticoagulation.
CaCl2-檸檬酸區域抗凝與全身抗凝的CVVH相比,CVVHD導致不必要的氯負荷。
Blood Purif 2024-09-01
Sustained Low-Efficiency Dialysis (SLED) with Regional Citrate Anticoagulation (RCA) and new dialysis equipment: a prospective study with serum citrate measurements and electrolyte monitoring.
使用區域檸檬酸抗凝劑 (RCA) 的持續低效率透析 (SLED) 及新型透析設備:一項前瞻性研究,包含血清檸檬酸測量和電解質監測。
J Nephrol 2025-02-01
Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study.
高出血風險患者的慢性血液透析中,Nafamostat mesylate 與區域檸檬酸抗凝的比較:一項單中心回顧性研究。
Ren Fail 2025-02-21
這項研究評估了 nafamostat mesylate (NM) 在高風險出血的血液透析患者中,作為抗凝劑的替代選擇,與檸檬酸相比。研究涵蓋196名患者,分析651次透析會議。結果顯示,使用NM的透析中,因凝血提前終止的情況顯著較少(0.84% vs. 5.19%),且重大凝血風險顯著降低(OR: 0.063)。更重要的是,NM並未增加重大出血事件的風險。因此,NM在預防凝血方面表現更佳,適合高風險出血的透析患者使用。
PubMedDOI
Development and validation of a risk prediction model for citrate accumulation in patients undergoing continuous renal replacement therapy with regional citrate anticoagulation.
針對接受區域檸檬酸抗凝治療的持續腎臟替代療法患者,檸檬酸累積風險預測模型的開發與驗證。
Blood Purif 2025-03-20